Glycosylation can be a critical quality attribute for protein therapeutics due to its extensive impact on product safety and efficacy. Glycan characterization is important in the process of protein drug development, from early stage candidate selection to late stage regulatory submission. It is also an indispensable part in the evaluation of biosimilarity. This review discusses the effects of glycosylation on the stability and activity of protein therapeutics, regulatory considerations corresponding to manufacturing and structural characterization of glycosylated protein therapeutics, and focuses on mass spectrometry compatible separation methods for glycan characterization of protein therapeutics. These approaches include hydrophilic interaction liquid chromatography, reversed-phase liquid chromatography, capillary electrophoresis, porous graphitic carbon liquid chromatography and two-dimensional liquid chromatography. Advances and novelties in each separation method, as well as associated challenges and limitations, are discussed at the released glycan, glycopeptide, glycoprotein subunit and intact glycoprotein levels.
Keywords: Capillary electrophoresis (CE); Glycan; Hydrophilic interaction liquid chromatography (HILIC); Mass spectrometry (MS); Porous graphitic carbon (PGC); Protein therapeutics and therapeutic monoclonal antibody; Reversed-phase liquid chromatography (RPLC); Two-dimensional liquid chromatography (2D-LC).
Copyright © 2019 Elsevier B.V. All rights reserved.